Converging evidence suggests that patients with bipolar disorder suffer from deficits in
neurocognitive functioning that persist, despite remission of acute affective symptoms. These
impairments contribute directly to functional disability, highlighting the need for
interventions above and beyond standard treatments in order to achieve a full inter-episode
recovery. The current study aims to investigate the safety and efficacy of a dopamine agonist
(pramipexole), on these persistent cognitive abnormalities in euthymic bipolar patients using
a placebo-controlled, adjunctive, 12-week trial design.